Tags

Type your tag names separated by a space and hit enter

Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system.
Can J Physiol Pharmacol. 2017 Oct; 95(10):1117-1124.CJ

Abstract

The renin-angiotensin system (RAS) generates, maintains, and makes worse hypertension and cardiovascular diseases (CVDs) through its biologically active component angiotensin II (Ang II), that causes vasoconstriction, sodium retention, and structural alterations of the heart and the arteries. A few endogenous vasodilators, kinins, natriuretic peptides, and possibly angiotensin (1-7), exert opposite actions and may provide useful therapeutic agents. As endothelial autacoids, the kinins are potent vasodilators, active natriuretics, and protectors of the endothelium. Indeed, the kallikrein-kinin system (KKS) is considered the dominant mechanism for counteracting the detrimental effects of the hyperactive RAS. The 2 systems, RAS and KKS, are controlled by the angiotensin-converting enzyme (ACE) that generates Ang II and inactivates the kinins. Inhibitors of ACE can reduce the impact of Ang II and potentiate the kinins, thus contributing to restore the cardiovascular homeostasis. In the last 20 years, ACE-inhibitors (ACE-Is) have become the drugs of first choice for the treatments of the major CVDs. ACE-Is not only reduce blood pressure, as sartans also do, but by protecting and potentiating the kinins, they can reduce morbidity and mortality and improve the quality of life for patients with CVDs. This paper provides a brief review of the literature on this topic.

Authors+Show Affiliations

a Department of Medical Sciences, University of Ferrara, Ferrara, Italy.b Department of Pharmacology and Physiology, Université de Sherbrooke, Québec, QC J1H 5N4, Canada.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28384411

Citation

Regoli, Domenico, and Fernand Gobeil. "Kallikrein-kinin System as the Dominant Mechanism to Counteract Hyperactive Renin-angiotensin System." Canadian Journal of Physiology and Pharmacology, vol. 95, no. 10, 2017, pp. 1117-1124.
Regoli D, Gobeil F. Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system. Can J Physiol Pharmacol. 2017;95(10):1117-1124.
Regoli, D., & Gobeil, F. (2017). Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system. Canadian Journal of Physiology and Pharmacology, 95(10), 1117-1124. https://doi.org/10.1139/cjpp-2016-0619
Regoli D, Gobeil F. Kallikrein-kinin System as the Dominant Mechanism to Counteract Hyperactive Renin-angiotensin System. Can J Physiol Pharmacol. 2017;95(10):1117-1124. PubMed PMID: 28384411.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system. AU - Regoli,Domenico, AU - Gobeil,Fernand, Y1 - 2017/04/06/ PY - 2017/4/7/pubmed PY - 2018/2/6/medline PY - 2017/4/7/entrez KW - angiotensin-converting enzyme inhibitors KW - angiotensines KW - angiotensins KW - cardiovascular diseases KW - inhibiteurs de l’enzyme de conversion de l’angiotensine KW - kinines KW - kinins KW - maladies cardiovasculaires KW - natriuretic peptides KW - peptides natriurétiques SP - 1117 EP - 1124 JF - Canadian journal of physiology and pharmacology JO - Can. J. Physiol. Pharmacol. VL - 95 IS - 10 N2 - The renin-angiotensin system (RAS) generates, maintains, and makes worse hypertension and cardiovascular diseases (CVDs) through its biologically active component angiotensin II (Ang II), that causes vasoconstriction, sodium retention, and structural alterations of the heart and the arteries. A few endogenous vasodilators, kinins, natriuretic peptides, and possibly angiotensin (1-7), exert opposite actions and may provide useful therapeutic agents. As endothelial autacoids, the kinins are potent vasodilators, active natriuretics, and protectors of the endothelium. Indeed, the kallikrein-kinin system (KKS) is considered the dominant mechanism for counteracting the detrimental effects of the hyperactive RAS. The 2 systems, RAS and KKS, are controlled by the angiotensin-converting enzyme (ACE) that generates Ang II and inactivates the kinins. Inhibitors of ACE can reduce the impact of Ang II and potentiate the kinins, thus contributing to restore the cardiovascular homeostasis. In the last 20 years, ACE-inhibitors (ACE-Is) have become the drugs of first choice for the treatments of the major CVDs. ACE-Is not only reduce blood pressure, as sartans also do, but by protecting and potentiating the kinins, they can reduce morbidity and mortality and improve the quality of life for patients with CVDs. This paper provides a brief review of the literature on this topic. SN - 1205-7541 UR - https://www.unboundmedicine.com/medline/citation/28384411/Kallikrein_kinin_system_as_the_dominant_mechanism_to_counteract_hyperactive_renin_angiotensin_system_ L2 - http://www.nrcresearchpress.com/doi/full/10.1139/cjpp-2016-0619?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -